vs
Side-by-side financial comparison of Orion Group Holdings Inc (ORN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Orion Group Holdings Inc is the larger business by last-quarter revenue ($233.2M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, Orion Group Holdings Inc posted the faster year-over-year revenue change (7.5% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $454.0K). Over the past eight quarters, Orion Group Holdings Inc's revenue compounded faster (20.5% CAGR vs 8.5%).
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ORN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $233.2M | $196.9M |
| Net Profit | $-240.0K | — |
| Gross Margin | 11.6% | 79.5% |
| Operating Margin | 2.2% | 1.2% |
| Net Margin | -0.1% | — |
| Revenue YoY | 7.5% | 5.1% |
| Net Profit YoY | -103.6% | — |
| EPS (diluted) | $-0.00 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $233.2M | $196.9M | ||
| Q3 25 | $225.1M | $179.5M | ||
| Q2 25 | $205.3M | $181.1M | ||
| Q1 25 | $188.7M | $168.9M | ||
| Q4 24 | $216.9M | $187.3M | ||
| Q3 24 | $226.7M | $168.6M | ||
| Q2 24 | $192.2M | $178.0M | ||
| Q1 24 | $160.7M | $167.1M |
| Q4 25 | $-240.0K | — | ||
| Q3 25 | $3.3M | $5.4M | ||
| Q2 25 | $841.0K | $-4.8M | ||
| Q1 25 | $-1.4M | $4.8M | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $4.3M | $-143.5M | ||
| Q2 24 | $-6.6M | $18.9M | ||
| Q1 24 | $-6.1M | $9.0M |
| Q4 25 | 11.6% | 79.5% | ||
| Q3 25 | 13.2% | 80.9% | ||
| Q2 25 | 12.6% | 77.4% | ||
| Q1 25 | 12.2% | 79.7% | ||
| Q4 24 | 14.0% | 78.7% | ||
| Q3 24 | 11.9% | 76.9% | ||
| Q2 24 | 9.5% | 75.1% | ||
| Q1 24 | 9.7% | 71.6% |
| Q4 25 | 2.2% | 1.2% | ||
| Q3 25 | 2.4% | 3.5% | ||
| Q2 25 | 1.7% | 4.7% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 4.4% | 13.2% | ||
| Q3 24 | 3.4% | -82.8% | ||
| Q2 24 | -1.4% | 15.9% | ||
| Q1 24 | -1.9% | 7.9% |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 1.5% | 3.0% | ||
| Q2 25 | 0.4% | -2.7% | ||
| Q1 25 | -0.7% | 2.8% | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 1.9% | -85.1% | ||
| Q2 24 | -3.4% | 10.6% | ||
| Q1 24 | -3.8% | 5.4% |
| Q4 25 | $-0.00 | $0.05 | ||
| Q3 25 | $0.08 | $0.12 | ||
| Q2 25 | $0.02 | $-0.11 | ||
| Q1 25 | $-0.04 | $0.10 | ||
| Q4 24 | $0.22 | $0.38 | ||
| Q3 24 | $0.12 | $-3.11 | ||
| Q2 24 | $-0.20 | $0.39 | ||
| Q1 24 | $-0.19 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $159.0M | $693.1M |
| Total Assets | $414.7M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6M | $238.4M | ||
| Q3 25 | $4.9M | $246.3M | ||
| Q2 25 | $1.7M | $445.9M | ||
| Q1 25 | $13.0M | $493.6M | ||
| Q4 24 | $28.3M | $484.6M | ||
| Q3 24 | $28.3M | $453.8M | ||
| Q2 24 | $4.8M | $404.2M | ||
| Q1 24 | $4.6M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | $33.4M | $580.5M | ||
| Q1 25 | $23.3M | $583.4M | ||
| Q4 24 | $23.2M | $585.3M | ||
| Q3 24 | $28.0M | — | ||
| Q2 24 | $60.3M | — | ||
| Q1 24 | $37.5M | — |
| Q4 25 | $159.0M | $693.1M | ||
| Q3 25 | $157.9M | $727.2M | ||
| Q2 25 | $153.2M | $757.8M | ||
| Q1 25 | $150.8M | $798.5M | ||
| Q4 24 | $150.7M | $778.3M | ||
| Q3 24 | $142.4M | $749.6M | ||
| Q2 24 | $111.1M | $879.3M | ||
| Q1 24 | $116.1M | $892.2M |
| Q4 25 | $414.7M | $1.3B | ||
| Q3 25 | $422.4M | $1.3B | ||
| Q2 25 | $432.7M | $1.5B | ||
| Q1 25 | $416.3M | $1.6B | ||
| Q4 24 | $417.3M | $1.6B | ||
| Q3 24 | $430.3M | $1.5B | ||
| Q2 24 | $414.0M | $1.6B | ||
| Q1 24 | $363.6M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | 0.22× | 0.77× | ||
| Q1 25 | 0.15× | 0.73× | ||
| Q4 24 | 0.15× | 0.75× | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $43.7M |
| Free Cash FlowOCF − Capex | $454.0K | $43.5M |
| FCF MarginFCF / Revenue | 0.2% | 22.1% |
| Capex IntensityCapex / Revenue | 5.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.8M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.8M | $43.7M | ||
| Q3 25 | $23.3M | $60.8M | ||
| Q2 25 | $-5.6M | $12.0M | ||
| Q1 25 | $-3.4M | $35.5M | ||
| Q4 24 | $13.4M | $33.1M | ||
| Q3 24 | $37.5M | $53.9M | ||
| Q2 24 | $-15.3M | $53.2M | ||
| Q1 24 | $-22.8M | $49.1M |
| Q4 25 | $454.0K | $43.5M | ||
| Q3 25 | $13.9M | $57.0M | ||
| Q2 25 | $-12.7M | $9.3M | ||
| Q1 25 | $-12.5M | $26.9M | ||
| Q4 24 | $9.9M | $31.0M | ||
| Q3 24 | $33.3M | $49.8M | ||
| Q2 24 | $-20.0M | $51.6M | ||
| Q1 24 | $-24.7M | $46.3M |
| Q4 25 | 0.2% | 22.1% | ||
| Q3 25 | 6.2% | 31.7% | ||
| Q2 25 | -6.2% | 5.1% | ||
| Q1 25 | -6.6% | 15.9% | ||
| Q4 24 | 4.6% | 16.6% | ||
| Q3 24 | 14.7% | 29.6% | ||
| Q2 24 | -10.4% | 29.0% | ||
| Q1 24 | -15.4% | 27.7% |
| Q4 25 | 5.7% | 0.1% | ||
| Q3 25 | 4.2% | 2.2% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 4.8% | 5.1% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 2.4% | 0.9% | ||
| Q1 24 | 1.2% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | 7.05× | 11.20× | ||
| Q2 25 | -6.61× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 1.98× | — | ||
| Q3 24 | 8.79× | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORN
| Construction | $117.0M | 50% |
| Light Commercial | $85.8M | 37% |
| Dredging | $18.1M | 8% |
| Structural | $8.0M | 3% |
| Specialty Services | $4.3M | 2% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
